In this context, we have tested, for the first time in rainbow trout, metformin, a common anti-diabetic drug, known to modify muscle and liver metabolism and to control hyperglycemia in mammals. In the present study, juvenile trout were fed with very high levels of carbohydrates (30% of the diet) for this species during 10 days followed by feeding with pellets supplemented with metformin (0.25% of the diet) for three additional days. Dietary metformin led to a significant reduction in postprandial glycemia in trout, demonstrating unambiguously the hypoglycemic effect of this drug. No effect of metformin was detected on mRNA levels for glucose transporter type 4 (GLUT4), or enzymes involved in glycolysis, mitochondrial energy metabolism, or on glycogen level in the white muscle. Expected inhibition of hepatic gluconeogenic (glucose-6-phosphatase, fructose-1,6-bisphosphatase, and phosphoenolpyruvate carboxykinase) mRNA levels was not found, showing instead paradoxically higher mRNA levels for these genes after drug treatment. Finally, metformin treatment was associated with higher mRNA levels and activities for lipogenic enzymes (fatty acid synthase and glucose-6-phosphate dehydrogenase). Overall, this study strongly supports that the induction of hepatic lipogenesis by dietary glucose may permit a more efficient control of postprandial glycemia in carnivorous fish fed with high carbohydrate diets.
glucose; anti-diabetic drug; muscle; liver; carnivorous fish TELEOST FISH SUCH AS THE RAINBOW trout (Oncorhynchus mykiss) are characterized by a limited efficiency to use even digestible carbohydrates (55) and are thus considered as "glucose intolerant" (21, 34) . Oral or intravenous administration of glucose or a carbohydrate-rich diet results in a persistent hyperglycaemia in various fish species, including rainbow trout (4, 8, 14, 15, 17, 31, 37) , and is also associated with elevated insulin levels, very much like in mammals (8, 17) . Insulin receptors are present in major insulin-responsive tissues, including white muscle, liver, and adipose tissues (19, 42, 43, 35) . Upregulation of insulin binding and tyrosine kinase activities is observed after insulin treatment and carbohydrate-rich diets, respectively (2, 19, 42, 43) . The persistent hyperglycemia in rainbow trout fed with carbohydrates despite the existence of insulin secretion and tissue receptors suggests an insulin resistance state comparable to that observed in humans with type II non-insulin-dependent diabetes mellitus.
Absorbed glucose is efficiently transported by enterocytes in the blood, as reflected by the induction of sodium-dependent glucose cotransporters in trout-fed carbohydrates (27) . In rainbow trout, a system similar to that proposed in mammals involved in the detection of changes in circulating glucose levels by pancreatic ␤-cells and glucose-excited neurons in the hypothalamus and the brain stem appears to be functional and inducible (48, 49) . Glucose uptake mediated by the facilitative insulin-regulated glucose transporter GLUT4 homolog in white muscle and fat tissues and by GLUT2 in liver are observed in trout (6, 9, 10, 30) . At the metabolic level, most key enzymes involved in carbohydrate metabolism are described in fish (7) . For some such as glucokinase (GCK; EC 2.7.1.2) (liver), phosphofructokinase (EC 2.7.1.11) (liver and muscle), and pyruvate kinase (PK; EC 2.7.1.40) (liver and muscle), their induction by dietary carbohydrates is similar to that described in mammalian systems (16, 38, 41) . However, data on other metabolic actors of glucose metabolism suggest the existence of an atypical regulation after carbohydrate intake by trout, including a lower capacity for glucose phosphorylation by hexokinases (HKs) in the muscle of fish than in mammalian species, which was further confirmed by the poor utilization of exogenous glucose as a glycogenic substrate in trout muscle (23, 26, 55) . In addition, carbohydrate-rich diets do not affect the activity or mRNA levels of key enzymes of trout hepatic gluconeogenesis, including glucose-6-phosphatase (G-6-Pase; EC 3.1.3.9), fructose-1,6-bisphosphatase (FBPase; EC 3.1.3.11) or phosphoenolpyruvate carboxykinase (PEPCK; EC 4.1.1.49) (27, 39, 40, 41) in contrast to mammals (12, 33, 51) . Such an impaired postprandial downregulation of insulinregulated gluconeogenic enzymes in rainbow trout fed with carbohydrates is similar to the insulin resistance observed in human patients with type II diabetes. We thus propose the hypothesis that dietary glucose intolerance in rainbow trout is mainly related to impaired transcriptional (down) regulation of hepatic gluconeogenic genes (27, 40, 41, 42) .
Metformin (1,1-dimethylbiguanide hydrochloride) is an antidiabetic drug used extensively for the treatment of human type 2 diabetes improving glucose homeostasis without modification of insulin secretion (28) . The major effect of metformin in mammals is an inhibition of gluconeogenesis by downregulating hepatic gluconeogenic mRNA levels through activation of AMP-activated protein kinase (AMPK) (53) . Treatment with metformin was reported in two cyprinid species, the common carp (Cyprinus carpio) and the zebrafish (Danio rerio), both known to be glucose tolerant (13, 22) . Our objective in this study was to analyze the effect of metformin in seemingly glucose-intolerant rainbow trout by feeding them with or without carbohydrates for 10 days followed by a metformin treatment for an additional 3 days. We analyzed mRNA levels for the gluconeogenic enzymes G-6-Pase, FBPase and mitochondrial (m) PEPCK 2, 6, and 24 h after the last feeding. Because metformin has other extragluconeogenic molecular targets in mammalian liver and muscle (20, 28) , we also studied the mRNA levels of the muscle GLUT4, three glycolytic enzymes [ 
METHODS

Fish and diets.
A 2-wk growth study was undertaken with groups of juvenile rainbow trout (15 fish/tank; initial body mass 90 g) reared in our experimental fish farm (INRA, St.-Pee, France) at 18°C under an artificial photoperiod (light from 8:00 A.M. to 8:00 P.M.). Three isocaloric diets were formulated and manufactured in our experimental unit (see Table 1 ). The diet ϩCho contained a high level of carbohydrate (30% of gelatinized starch) and the diet ϪCho was devoid of carbohydrate. A third diet ϩChoϩMet was supplemented with metformin (Merck, Paris, France) at a level of 0.25% in the diet [to give 50 mg metformin ⅐ day Ϫ1 ⅐ kg fish Ϫ1 , a common dose used in mammalian studies (28) ]. Fish were hand-fed two times daily at 2% body weight for 10 days with the ϩCho diet in four tanks or with the ϪCho diet in two tanks. Following this 10-day period, the fish were fed for an additional 3 days with either ϩCho or ϪCho diets while two tanks of fish fed initially with ϩCho were fed with the ϩChoϩMet diet.
Tissue and blood sampling. At the end of the trial, six fish per group (3/tank) were randomly sampled 2, 6, and 24 h after the meal to follow the postprandial phase. Trout were killed by a sharp blow to the head. Blood was removed from the caudal vein and centrifuged (3,000 g, 5 min), and the recovered plasma was immediately frozen and kept at Ϫ20°C. Gut content of each fish was systematically checked to assert that the fish sampled had effectively consumed the diet. Liver and a sample of dorsoventral white muscle were immediately dissected, weighed, immediately frozen in liquid nitrogen, and kept at Ϫ80°C. Chemical composition of the diets. The experimental diets were analyzed using the following procedures: dry matter after drying at 105°C for 24h, starch by the glucoamylase glucose oxidase method (54), and gross energy using an adiabatic bomb calorimeter (IKA, Heitersheim Gribheimer, Germany). Protein content (N ϫ 6.25) was determined by the Kjeldahl method after acid digestion.
Plasma metabolites and glycogen content. Plasma glucose concentration was determined using the glucose oxidase method with a Beckman glucose analyzer (Beckman II). Plasma triglyceride levels were measured by a colorimetric enzyme assay using hepatic lipase (EC 3.1.1.3), glycerokinase (EC 2.7.1.30), glycerol-3-phosphate oxidase (EC 1.1.3.21), and peroxidase (EC 1.1.11) (PAP 150 kit; Biomérieux, Marcy-l'étoile, France). Plasma free fatty acid levels were measured by a colorimetric enzyme assay using acyl-CoA synthetase, acyl-CoA oxidase, and peroxidase (Wako Nefa C kit; Wako Chemicals, Neuss, Germany). Liver and muscle glycogen were determined according to Ref. 25 .
Enzyme activities. Estimates of lipogenic FAS and G-6-PDH activities were undertaken according to Ref. 50 . Glycolytic (HK and PK) enzyme activities were measured as described by Kirchner et al. (24) . Enzyme activities are expressed per milligram of protein. Protein concentration was determined using a Bradford protein assay kit (Bio-Rad, München, Germany) with BSA as standard. All of the estimates for each individual were performed in duplicate.
mRNA level analysis by real-time quantitative RT-PCR. Total RNA was extracted from rainbow trout liver and white muscle using TRIzol reagent (Invitrogen, Carlsbad, CA). Total RNA (1 g) was reverse transcribed into cDNA with the Superscript III RNAse H Reverse Transcriptase kit (Invitrogen) using oligo(dT) primers. mRNA levels were determined by real-time quantitative RT-PCR (q-PCR) using the iCycler iQ (Bio-Rad, Hercules, CA). Analyses were performed on 10 l of the diluted cDNA using the iQ TM SYBR Green Supermix (Bio-Rad), in a total PCR reaction volume of 25 l, containing 200 nM of each primer. Primers were designed to overlap an intron if possible (Primer3 software) using known sequences in nucleotide databases (Table 2) as previously described (47) . Relative quantifica- ajpregu.physiology.org tion of the target gene transcript was done using ef1␣ mRNA level as described previously (36) , which was stably expressed in this experiment. Thermal cycling was initiated with incubation at 95°C for 90 s using hot-start iTaq DNA polymerase activation; 35 steps of PCR were performed, each one consisting of heating at 95°C for 20 s for denaturing, and at specific annealing and extension temperatures as noted on Table 2 . Following the final PCR cycle, melting curves were systematically monitored (55°C temperature gradient at 0.5°C/s from 55 to 94°C) to ensure that only one fragment was amplified. Samples without reverse transcriptase and samples without RNA were run for each reaction as negative controls. For each sample, two RTs were performed, and for each RT two PCRs were done.
Data analysis. Data are presented as means Ϯ SD. Except for q-PCR data analysis, we analyzed the effect of the three different dietary treatments independently at each postprandial sampling time using a Kruskal-Wallis nonparametric test. Relative quantification of the target gene transcript with the ef1␣ reference gene transcript was made following the Pfaffl method with the Relative Expression Software tool (REST) (45, 46) . This mathematical algorithm computes an expression ratio based on q-PCR efficiency and the crossing point deviation of the unknown sample vs. a control group: R ϭ [(E target gene )⌬CT Target gene (mean control Ϫ mean unknown sample)]/ [(EEF1␣)⌬CT EF1␣(mean control Ϫ mean unknown sample)] where E is PCR efficiency determined using a standard curve of cDNA serial dilutions (cDNA dilutions from 1/16 up to 1/512) and ⌬C T is the crossing point deviation of an unknown sample vs. a control. Statistical differences in mRNA levels between control and sample were evaluated as group means by randomization tests (46) using REST software; 2,000 random allocations were performed, and significant differences were considered at P Ͻ 0.05. For the comparison between fish fed with and without carbohydrate, the control group is the carbohydrate-free group, whereas, for the comparison between fish treated with or without metformin, the control group is the metforminfree group.
RESULTS
Rainbow trout were killed 13 days after the dietary treatments (with or without carbohydrates), including the last 3 days with metformin for the drug-treated group. Data on postprandial plasma glucose, free fatty acids, and triglycerides at 2, 6, and 24 h after the meal are presented in Fig. 1 . Because the diets were isolipidic, no significant differences were observed for plasma free fatty acids and triglyceride levels between fish fed with or without carbohydrate. Hyperglycemia (up to 16.5 mmol/l) was observed in fish fed with carbohydrates 2 and 6 h after feeding (Fig. 1A) . Metformin intake during the 3 days before sampling prevented the observed increase in plasma glucose level 2 and 6 h after the meal (Fig.  1A) and in plasma free fatty acids 6 h after the meal (Fig. 1B) compared with fish fed the ϩCho diet.
Our data clearly demonstrate elevated levels of hepatic and muscle glycogen content in fish fed with carbohydrate compared with those fed without carbohydrate (3-and 10-fold higher levels in muscle and liver, respectively) (Fig. 2, A and  B) . However, dietary metformin had no specific effect on glycogen content (Fig. 2, A and B) . The changes in hepatic glycogen were correlated with the hepatosomatic index (3 and 0.7% in fish with or without carbohydrate, respectively).
Estimates of mRNA levels for enzymes involved in intermediary metabolism. Data on gene mRNA levels for enzymes involved in glucose transport (GLUT4), glycolysis (HK and PK), and oxidative metabolism (HOAD and CS) in the muscle of fish fed with and without carbohydrate 6 and 24 h after the last feeding are reported in Table 3 . Regardless of the experimental conditions (with or without carbohydrate), no changes in relative transcript levels were noted for these genes in white muscle (P Ͼ 0.05). There was also no variation of mRNA levels linked to the metformin intake for these candidate proteins (Table 4) .
Regarding regulation of mRNA levels for enzymes of hepatic intermediary metabolism (glycolysis, gluconeogenesis, lipogenesis) (Table 5) , carbohydrate intake was associated with a large induction of the GCK mRNA level (on-off regulation) and unexpectedly a two-and fourfold inhibition of PK mRNA levels 6 and 24 h after the last feeding, respectively (Table 5) . GenBank accession no. or sigenae accession nos. in parentheses: EF1␣, elongation factor 1␣ (AF498320); GCK, glucokinase (AF135403); PK, pyruvate kinase, liver isoform (AF246146); mPEPCK, phosphoenolpyruvate carboxykinase, mitochondrial isoform (AF246149); G-6-Pase 1, glucose 6-phosphatase 1 (tcay0019b.d.18_3.1.s.om.8.1-1693); G-6-Pase 2, glucose 6-phosphatase 2 (AF120150); FBPase, fructose-1,6-bisphosphatase (AF333188); FAS, fatty acid synthase (tcab0001c.e.06_5.1.s.om.8); G-6-PDH, glucose-6-phosphate dehydrogenase (CA351434); HK, hexokinase (AY864082); PK-M, pyruvate kinase, muscle isoform (tcav0004c.c.07_3.1.om.4); HOAD, hydroxyacyl-CoA-dehydrogenase (tcad0001a.i.15_3.1.om.4); CS, citrate synthase (TC89195); GLUT4, glucose transporter type 4 (AF247395). For the gluconeogenic pathway, G-6-Pase 1 and 2 mRNA levels were not affected by dietary carbohydrate, whereas a large significant inhibition by dietary carbohydrate of FBPase (8-to 7-fold) and mPEPCK (4-to 2-fold) mRNA levels was observed 6 and 24 h after the last feeding (Table 5 ). Among the lipogenic enzymes, FAS mRNA level was unaffected, but G-6-PDH mRNA level was induced by twofold in the carbohydrate-rich diet group (Table 5) .
R709 EFFECT OF METFORMIN IN CARBOHYDRATE-FED TROUT
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Specific metformin effects on hepatic enzyme mRNA levels are reported in Table 6 . Metformin intake did not affect mRNA levels for the two glycolytic enzymes GCK and PK or the last enzyme of glucose production, G-6-Pase (isoforms 1 and 2). (2, 6 , and 24 h after meal) plasma metabolites in fish fed with 30% carbohydrates (gray bar), 30% carbohydrates ϩ metformin (black bar), or without carbohydrates (white bar). Fish were fed with or without carbohydrates for 10 days followed by metformin for an additional 3 days. A: glucose. B: free fatty acids. C: triglycerides. Values represent means ϩ SD (n ϭ 6 experiments). Mean values for a selected group not sharing a common letter differ (P Ͻ 0.05; Kruskal-Wallis nonparametric test). Statistical differences in gene expression were evaluated between group means (n ϭ 6 samples/group) by randomization tests using REST software (46) : ϩ and Ϫ signs mean that the target gene is expressed at a lower or higher level, respectively, with respect to the control gene ef1␣. No significant differences were observed (P Ͼ 0.05).
However, mRNA levels of the gluconeogenic enzymes FBPase and mPEPCK (up to 4-and 2-fold for FBPase and mPEPCK, respectively) and lipogenic enzyme FAS (9-fold) were induced in metformin-fed trout. A weaker but significant increase (1.8-fold) was also observed 6 h after feeding for G-6-PDH mRNA levels, known to produce NADPH necessary for lipogenesis in fish.
Activities of enzymes involved in intermediary metabolism. Activities for HK and PK were assessed (Fig. 3) , HK because of its well-known weak activity in rainbow trout muscle and its proposed role as a bottleneck in dietary glucose utilization in this species (55) , and PK because of its atypical decreased mRNA levels in trout-fed carbohydrates (this study) and its enhanced activity after metformin treatment in mammals (1). HK and PK enzymes were measured 6 h after the last feeding to coincide with the higher level of plasma glucose at this sampling time (Fig. 1A) . In white muscle, no changes in HK and PK activities were detected based on diet treatments (Fig.  3, A and B) . In contrast, hepatic PK activities were reduced in fish fed carbohydrate compared with those fed without carbohydrate (P ϭ 0.03) but without any effect of metformin (Fig. 3B) .
The activities of the two lipogenic enzymes FAS and G-6-PDH were assessed 24 h after the last feeding, which correspond to the time of molecular activation of these two lipogenic genes (Table 6 ). Although there was no effect of diet treatment on hepatic FAS activities (Fig. 4B) , hepatic G-6-PDH activities increased with (ϩChoϩMet) Ͼ (ϩCho) Ͼ (ϪCho) (Fig. 4C) .
DISCUSSION
This study used the anti-diabetic drug, metformin, known to play a key role in downregulation of hyperglycemia in mammals to determine if it would improve glucose homeostasis in rainbow trout after dietary carbohydrate intake. Because metformin acts mainly at the molecular level, we analyzed mRNA levels of key metabolic actors in two targets tissues (liver and muscle) known to play important roles in the control of postprandial glycemia.
Effect of a very high level of dietary carbohydrates on mRNA levels in muscle and liver.
The ingestion of dietary carbohydrate induced a dramatic but transient (at 2 and 6 h after feeding only) hyperglycemia (up to 16.5 mmol/l) in the rainbow trout consistent with the large body of evidence on the absence of a strict control over glycemia in glucose-challenged rainbow trout (21, 38, 55) . The absence of changes in mRNA levels for GLUT4, HK, PK, HOAD, and CS with high dietary digestible carbohydrate intake confirmed the low capacity of molecular adaptation of white muscle to a high influx of glucose previously observed (21) . We, however, found a higher glycogen content in muscle of carbohydrate-fed fish, suggesting enhanced glucose storage in this tissue but presumably insufficient to avoid hyperglycemia, as previously suggested (55) .
The response of liver in contrast to the white muscle to high carbohydrate intake was more dramatic but somewhat surprising. Indeed, a huge induction of GCK mRNA level, a more modest induction of G-6-PDH, but also the absence of regulation of G-6-Pase and FAS were detected, confirming previous trends described in trout (5, 38, 39) . However, the reduced mRNA levels of glycolytic PK (confirmed by the enzymatic activities) and gluconeogenic mPEPCK/FBPase noted for the first time in rainbow trout after carbohydrate intake are in contrast to our previous data (40, 41) . We have no clear explanation for these conflicting results, but we suspect that the very high levels of carbohydrates used in this study (30%) associated with the very high postprandial glycemia level (16.5 Statistical differences in gene expression were evaluated between group means (n ϭ 6 samples/group) by randomization tests using REST software (46) . No significant differences were observed (P Ͼ 0.05). Statistical differences in gene expression were evaluated between group means (n ϭ 6 samples/group) by randomization tests using REST software (46). *Significant difference, P Ͻ 0.05. ajpregu.physiology.org mmol/l) as well as the relatively short study period (13 days) may be responsible for these conflicting responses. We cannot exclude also a potential effect of the relatively low level of dietary protein (42 vs. 61%; see Table 1 ) in these diets on these genes especially for the regulation of gluconeogenesis, as previously suggested (25) .
Further studies are needed to better understand the atypical molecular regulation of some enzymes by dietary carbohydrate in rainbow trout. Indeed, the inhibition of PK mRNA level (last enzyme of the glycolytic pathway), the absence of inhibition of G-6-Pase mRNA level (last enzyme of the hepatic glucose production), and the absence of induction of the FAS mRNA level (a key lipogenic enzyme) are in contrast to data from mammalian studies (11, 33, 52) . Overall, these observations could have important consequences to explain the low dietary glucose use by the trout liver.
Effect of metformin on mRNA levels in muscle and liver of fish-fed carbohydrates. Metformin is a common human antidiabetic drug used to control glycemic levels in the face of hyperglycemia. The hypoglycemic role of metformin in carbohydrate-fed rainbow trout as reported here is the first-ever report of such a strong effect. Our data are consistent with a decrease in lypolysis or a higher fatty acid uptake in fish fed with metformin as reflected by the lower level of plasma free fatty acids 6 h after feeding. Overall, the changes in postprandial profiles of these circulating metabolites (glucose, free fatty acids) in trout treated with metformin are in accordance with the data obtained in mammals (28, 44) ; it has been proposed that the hypoglycemic effect of metformin in mammals could be (at least partially) due to the lower intracellular availability of fatty acids (through the inhibition of lypolysis), lower fatty acid oxidation, and consequently a better use of glucose as an energy source.
Metformin has a major impact on regulating glycemia by acting at the molecular level in target tissues (e.g., liver and muscle), specifically suppressing hepatic gluconeogenesis but also affecting other areas, including energy/lipid metabolism and glucose transport (28) . Looking for potential causative factors to explain the hypoglycemic effects of metformin in rainbow trout, the following points are worth considering. First, the hypoglycaemic effect of metformin was not due to a global enhanced efficiency or capacity to store glycogen in liver and muscle (28) . Second, we found no higher mRNA levels of the actors playing key roles in glucose transport in muscle (GLUT4) or in muscle and liver glycolysis (HK and PK) to explain a better glucose catabolism linked to the metformin intake (28, 29) . Third, no changed mRNA levels for at least one key enzyme involved in mitochondrial lipid ␤-oxidation (HOAD) were detected to suggest a better use of glucose as an energy source in metformin-treated fish (3, 28, 44 ). Finally, an increased level of hepatic gluconeogenic enzyme mRNA for FBPase and PEPCK was found in contrast to mammals (28, 44, 53) . Indeed, this latter point is intriguing, since molecular inhibition of gluconeogenesis, through activation of the kinases, LKB1 and AMPK in liver (18, 53) , is the main effect of metformin in mammals leading to the hypoglycemic action of this drug. The downregulation of gluconeogenesis by metformin was observed in two other fish species, the zebrafish and common carp, species generally recognized as more glucose tolerant than trout. In these two species, an inhibition of PEPCK mRNA level and glucose production from [ 14 C]alanine, respectively, was demonstrated after metformin treatment (13, 22) . These reports suggest that the absence of the common downregulation of gluconeogenic gene transcription by metformin is specific to the rainbow trout species, possibly linked to its poor capacity to use a high level of glucose.
In contrast to the previous data, which cannot explain the hypoglycemic effect of metformin in rainbow trout, we did observe that metformin intake was associated with higher mRNA levels for two key enzymes involved in hepatic lipogenesis in fish (5), G-6-PDH [the major NADPH producer for lipogenesis in fish liver (5)] and FAS. These molecular data were confirmed at the enzyme level for G-6-PDH but not for FAS; for the latter, this could be due either to posttranscriptional regulations or to the latter postprandial induction of the gene transcription, since no differences were detected 6 h after feeding, only at 24 h after feeding. Thus our data support a higher potential of lipogenesis in trout liver that may improve glucose biotransformation to fatty acids, a process thought not to be very efficient in rainbow trout (5) . We cannot exclude the possibility that G-6-PDH as a key actor within the pentose phosphate pathways could be directly involved in glucose utilization and transformation of pentoses. Moreover, it is interesting to note that the putative metformin-linked increase of lipogenesis in trout is in contrast with mammalian studies for which there was inhibition of lipogenesis after metformin intake linked to AMPK activation (18, 28) .
Overall, metformin appears to upregulate the mRNA level of enzymes linked to the gluconeogenic and lipogenic metabolic pathways, suggesting the existence of specific metabolic regulation in the liver of carnivorous animals. In particular, the induction of the hepatic lipogenic pathway could be the major mechanism to better use dietary glucose in rainbow trout.
Further studies are necessary to analyze more precisely the mechanisms of action of metformin in rainbow trout, including the analysis of AMPK enzyme (an energy/nutrient sensor) known to be a key mediator of metformin action (18, 53) .
Perspectives and Significance
This study provides original data related to the control of glycemia in carnivorous fish fed with carbohydrate. Contrary to our hypothesis regarding the importance of hepatic gluconeogenesis in glucose homeostasis, our study using high digestible carbohydrate diets and metformin indicates that hepatic lipogenesis could be an efficient metabolic pathway to transform glucose (in excess) to lipids (fatty acids) and thus to limit postprandial hyperglycemia. This could be very important because, in contrast to glucose, the utilisation of lipids as a source of energy in fish is considered very efficient, especially during swimming (32) . Finally, this study supports the existence of specific regulation of intermediary metabolism in trout, as reflected by the inhibition of PK mRNA level by carbohydrates and the induction of gluconeogenic and lipogenic enzymes by metformin, which could be related to the carnivorous habits of the species. Certainly, the use of metformin as a drug to modulate hyperglycemia during a carbohydrate diet in this carnivorous species needs to be further examined, especially as it relates to lipogenesis. In addition, research in rainbow trout regarding the main transcription factors regulating lipogenesis, including the sterol regulatory element-binding protein 1 (SREBP1) and carbohydrate-response element-binding protein (ChREBP) could further our understanding of the glucose-intolerance of this species.
